CoChat

Multiscale Framework for Imaging Radiolabeled Therapeutics

Open access
Natarajan, Arutselvan, Türkcan, Silvan, Gambhir, Sanjiv S., Pratx, Guillem · 2015 · Molecular Pharmaceutics

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The resistance of a tumor to a drug is the result of bulk properties of the tumor tissue as well as phenotypic variations displayed by single cells. Here, we show that radioisotopic detection methods, commonly used for tracking the tissue distribution of drug compounds, can be extended to the single-cell level to image the same molecule over a range of physical scales. The anticancer drug rituximab was labeled with short-lived radionuclides (89Zr/64Cu) and its accumulation at the organ level was imaged using PET in a humanized transgenic mouse model of non-Hodgkin’s lymphoma. To capture the distribution of the drug at a finer scale, tissue sections and single living cells were imaged using radioluminescence microscopy (RLM), a novel method that can detect radionuclides with single-cell resolution. In vivo PET images (24 h postinjection) showed that [89Zr]rituximab targeted the intended site of human CD20 expression, the spleen. Within this organ, RLM was used to resolve radiotracer accumulation in the splenic red pulp. In a separate study, RLM highlighted marked differences between single cells, with binding of the radiolabeled antibody ranging from background levels to 1200 radionuclides per cell. Overall, RLM images demonstrated significantly higher spatial resolution and sensitivity than conventional storage-phosphor autoradiography. In conclusion, this combination of PET and RLM provides a unique opportunity for exploring the molecular mechanism of drugs by tracking the same molecule over multiple physical scales, ranging from single living cells to organs substructures and entire living subjects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.molpharmaceut.5b00392

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 19

Metadata

Authors
Natarajan, A., Türkcan, S., Gambhir, S. S., & Pratx, G.
Affiliations
  • Stanford Medicine (US)
  • Stanford University School of Medicine , 1050 Arastradero Rd , , ,
Corresponding author
Pratx, Guillem
Venue
Molecular Pharmaceutics
Published
2015-10-13
Volume
12
Issue
12
Pages
4554-4560
ISSN
  • 1543-8384 (ISSN-L)
  • 1543-8392
OpenAlex
W2409875238
Cited by
19
References
24
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 8 · 2016: 4
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • Molecular Pharmaceutics (publishedVersion, other-oa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (R01CA186275)
  • Congressionally Directed Medical Research Programs (W81XWH-14-1-0288)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Detection and Scintillator Technologies
Keywords
rituximab, zirconium-89, copper-64, positron emission tomography, single-cell imaging, non-Hodgkin lymphoma, CD20, splenic red pulp, chemoresistance, multiscale imaging
MeSH terms
Rituximab, Animals, Antineoplastic Agents, Autoradiography, Disease Models, Animal, Humans, Lymphoma, Non-Hodgkin, Mice, Transgenic, Radioisotopes, Tissue Distribution, Antigens, CD20, Radiopharmaceuticals, Positron-Emission Tomography, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.